Cessatech

Highlights Q3-2023 Report

Third quarter financial results 2023 (1 July - 30 September):

• Net revenue was KDKK 0
• Operating result was KDKK -5.811
• Net result was KDKK -6.609
• Cash at bank end of the period was KDKK 5.192
• Earnings per share* was KDKK -0,48
• Solidity** was 66%

The Company has advanced well with its planned activities

• Last participant dosed in pivotal trail 0205
• Agreement with EMA on PIP for CT002
• Loan facility agreement to support US launch of CT001
• US planning & preparation CT001 launch
• Finalization of Study 0202 with competent authorities in selected countries

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 September 2023
amounted to 13.788.755 shares, the average number of shares during the second quarter was 13.788.755. 
**Solidity: Total equity divided by total capital and liability

Comment from CEO, Jes Trygved: We were pleased to have the last participant enrolled in the pivotal study 0205 during Q3 2023. This was an important milestone for the Company, and we look forward to presenting top-line results towards the end of the year. In addition, our  Paediatric Investigation plan for CT002 was agreed with the European regulatory authorities, allowing us to initiate development of this second asset in our pipeline. Our focus is also very much on the planning and preparation for the US launch of CT001 where we expect to book our first income already in 2024. To have a marketed product available for patients in just three years since the company was founded is impressive and I would like to thank the team for its efficiency, hard work and commitment for making this possible.